Welcome to our dedicated page for Molecular Templates news (Ticker: MTEM), a resource for investors and traders seeking the latest updates and insights on Molecular Templates stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Molecular Templates's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Molecular Templates's position in the market.
Molecular Templates (Nasdaq: MTEM) announced a successful capital raise of approximately $43 million through its At-the-Market facility. The company sold around 3.6 million shares at $12.00 each, with the proceeds aimed at advancing its product pipeline, including MT-3724, MT-5111, TAK-169, and MT-6402. Cantor Fitzgerald & Co. served as the sales agent for this transaction. The shares were issued under an effective shelf registration statement filed previously.
Molecular Templates (MTEM) announced updates on its pipeline during the AACR Virtual Annual Meeting 2020. Four posters were presented, highlighting preclinical data on engineered toxin bodies (ETBs) targeting HER2-positive cancers, regulatory T cells, SLAMF7, and CD45. The Phase I study of MT-5111 shows promising results with no dose-limiting toxicities and well-tolerated treatment. MT-6402 is set for IND filing in the second half of 2020. A conference call discussing further details is scheduled for June 25, 2020.
Molecular Templates (MTEM) has secured a $45 million debt financing facility from K2 HealthVentures. The initial $15 million tranche has been received, which partially repaid existing debts. Future tranches totaling $30 million depend on milestone achievements and lender consent. This funding will enhance MTEM's balance sheet and provide financial flexibility to expand its pipeline and manufacturing capacity. The company focuses on developing targeted biologic therapeutics using engineered toxin bodies (ETBs) for cancer treatment.
Molecular Templates (Nasdaq: MTEM) announced the presentation of new preclinical data at the AACR Virtual Annual Meeting II scheduled for June 22-24, 2020. The data includes insights on MT-6402, an engineered toxin body targeting PD-L1, which demonstrates unique tumor-targeting capabilities. The findings suggest that MT-6402 can destroy PD-L1+ tumor cells, deliver foreign antigens to enhance immune visibility, and activate the immune system. Four posters detailing these advancements will be available online at the AACR event.
Molecular Templates, Inc. (Nasdaq: MTEM) announced participation in two upcoming virtual healthcare conferences. The Bank of America Securities Virtual Healthcare Conference is scheduled for May 14, while the UBS Virtual Healthcare Conference will follow on May 18 at 9:10 AM Eastern Time. Molecular Templates focuses on developing engineered toxin bodies (ETBs), offering innovative therapies against cancer and serious diseases. Further details and webcast links are available in the press announcement.
Molecular Templates (Nasdaq: MTEM) announced that its 2020 Annual Meeting of Stockholders will be held virtually on May 28, 2020, at 8:30 a.m. ET due to COVID-19. Eligible stockholders, recorded as of April 8, 2020, must register in advance at www.proxydocs.com/MTEM by May 26, 2020, for meeting access. The change to a virtual format aims to ensure health safety. The meeting details are outlined in the proxy materials, which also provide participation instructions.